• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·HESTERBIO.NS
Share

Hester Biosciences Limited Stocks

₹ 2450Last Updated 21.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 216.35M

₹ 2450
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both domestic and international markets, structured around two primary divisions: Poultry Healthcare and Animal Healthcare. Its extensive range of poultry vaccines targets numerous conditions, including Newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reovirus infections, Marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, and avian encephalomyelitis. For larger animals, Hester Biosciences provides vaccines designed to combat ailments such as Goat Pox, Peste des Petits Ruminants (PPR), Brucellosis, Mastitis, Metritis, various infectious diseases, reproductive disorders, theileriosis, and parasitic infestations. Beyond vaccines, the company's product portfolio encompasses vital feed supplements like toxin binders, trace minerals, enzyme preparations, and bypass fats. It also supplies disinfectants for maintaining farm hygiene and sanitizing equipment, along with water purification solutions. Nutritional support products are offered, including mineral mixtures, fertility boosters, and growth tonics. A significant portion of their offerings consists of herbal preparations, featuring growth promoters, natural alternatives to choline chloride, stress and immunity enhancers, respiratory aids, liver tonics, wound healing agents, uterine and digestive tonics, anti-bloat remedies, ectoparasiticides, and treatments for anti-mastitis and anti-prolapse conditions.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 19:20

IBM has lowered its revenue growth forecast. How is the company trying to reassure investors?

23.07.2026 19:02

Nasdaq has tightened its rules. Nearly 200 small companies are at risk of delisting.

23.07.2026 18:50

U.S. stocks plummeted at the opening bell: tech giants and oil prices dragged the indices down

23.07.2026 18:23

The price of Brent crude oil exceeded $100 per barrel for the first time since May

23.07.2026 17:30

EasyJet's profits fell by 70%. Why did its stock jump 5%?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026